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Abstract 
During the past decade, researchers have shown an increased interest in 
multifunctional nanomaterials. Magnetic Nanoparticles (MNP) have been one of the 
most attractive types of nanomaterials used in different fields, as in environmental 
protection and biomedical applications. These applications include drug delivery, 
magnetic resonance imaging, magnetic hyperthermia, among others. MNPs have been 
synthesized by various methods. Amongst the most common may be referred: thermal 
decomposition, microemulsion, coprecipitation, solution combustion and sonochemical 
synthesis. 
The main objective of this MSc thesis is the development of biocompatible 
MNPs with high potential for the controlled release of drugs. For this purpose, a 
magnetic core based on magnetite is developed by two different approaches of Solution 
Combustion Synthesis. In the first approach, the synthesis of MNPs is obtained by 
reduction of Fe (III) using citric acid, and the in second approach, the MNPs are 
synthesized using tangerine peel extract for the reduction of Fe (III). However, the 
material produced with the extract was not magnetic, and it was decided to not continue 
the methodology with it.  Then, the magnetic core, produced with citric acid, is coated 
with a resin prepared from formaldehyde, resorcinol and TEOS, which is later 
carbonized by pyrolysis at 600 ºC. Subsequently, the silica generated from TEOS is 
removed by etching with NaOH in order to create a void inside the particle, which take 
the known yolk-shell shape. Finally, the materials are functionalized with nitric acid and 
subsequent pluronic F-127, for its biocompatibility and dispersibility. These materials 
are then assessed in the controlled release of two different drugs to test the potential of 
the developed magnetic nanostructures for drug delivery applications: Doxorubicin 
(DOX) and Omeprazole (OME). Drug Loading Capacity and Efficiency of 
0.936 μg·μg -1  and 93.6% for DOX and 0.335 μg·μg-1 and 33.5% for OME are obtained 
at pH 7.4, respectively. Finally, the drug release is tested at the pH of the normal tissue 
(pH 7.4) and at the pH of the extracellular environment of the tumor (pH < 6.5), 
simulating different circumstances of the human body. 
Keywords: nanomaterials; magnetic; biomedicine; solution combustion synthesis; drug 
delivery. 
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Resumo 
Durante a última década, os pesquisadores tem mostrado um interesse crescente 
em nanomateriais multifuncionais. As nanopartículas magnéticas (MNPs) tem surgido 
assim como um dos tipos de nanomateriais mais promissores para diversos fins, 
podendo ser utilizado, por exemplo, em proteção ambiental e em aplicações biomédicas. 
De entre estas aplicações podemos citar a libertação controlada de fármacos, a 
ressonância magnética, o tratamento hipertermia magnética, entre outros. As MNPs 
podem ser sintetizadas das mais diversas maneiras, entre as quais as mais comuns são: 
decomposição térmica, microemulsão, coprecipitação, síntese por combustão de solução 
e síntese sonoquimica. 
O principal objetivo desta tese é desenvolver MNPs biocompatíveis com grande 
potencial para a libertação controlada de fármacos. Para isso, será produzido um núcleo 
magnético, feito de magnetite, considerando duas abordagem de síntese de combustão 
de solução. Na primeira abordagem, as MNPs são produzidas reduzindo o Fe (III) com 
ácido cítrico. Na segunda abordagem, o agente responsável pela redução dos iões de 
Fe (III) é um extrato de tangerina, porém utilizando esse agente o material produzido 
não era magnético, e optou-se por não continuar a metodologia com ele. Em seguida, o 
núcleo magnético, produzido com o ácido cítrico, é revestido com uma resina preparada 
a partir de formaldeído, resorcinol e TEOS, que posteriormente é carbonizada por 
pirólise a 600 ºC. Após a carbonização, a sílica gerada a partir de TEOS é removida 
com NaOH, a fim de criar um vazio no interior do material, que assume a forma 
conhecida como casca de gema. Finalmente, os materiais são funcionalizados com ácido 
nítrico e subsequente plurônico F-127, para obter características de biocompatibilidade 
e dispersibilidade. Os materiais sintetizados são então avaliados na libertação controlada 
de dois fármacos, para testar o potencial das nanoestruturas magnéticas nessa aplicação 
biomédica: Doxorrubicina (DOX) e Omeprazol (OME). Obteve-se uma capacidade de 
carga dos fármacos e uma eficiência de 0,936 μg·μg-1 e 93,6% para DOX e 
0,335 μg·μg -1 e 33,5% para OME, respetivamente, obtidas a pH 7,4. Finalmente, a 
libertação do fármaco é testada no pH do tecido normal (pH 7,4) e no pH do ambiente 
extracelular do tumor (pH < 6,5), simulando diferentes circunstâncias do corpo humano. 
Palavras-chave:  nanomateriais; magnético; biomedicina; síntese de combustão de 
solução; libertação de fármacos.  
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1 Introduction 
 Magnetic nanoparticles (MNPs) have emerged as promising advanced functional 
materials for a wide field of potential applications, such as catalysis, water treatment, 
environmental remediation, biotechnology/biomedicine, magnetic recording media, 
electromagnetic wave absorption and magnetic sensors 1,2. Multiple techniques have 
been developed to prepare iron nanoparticles, including thermal decomposition, 
sonochemical decomposition, vapor phase condensation and solution combustion 2. In 
recent years, the synthesis by solution combustion has become a promising candidate 
for the preparation of a large variety of nanoparticles 3. It is considered a time/energy 
saving methodology for the preparation of inorganic nanopowders with high reactivity 
and tailored defects 4. In alternative to the traditional solution combustion synthesis with 
chemical reductants, green routes using plant extracts emerged as environmentally 
friendly ways to synthesize MNPs. Plant extracts are used to prepare MNPs, since there 
are no harmful agents to be discarded 5,6. 
In this work, the synthesized nanoparticles will be used as magnetic cores, 
further coated with carbon in yolk-shell structures, with the carbon-based coating, in 
relation to other coatings, showing better chemical and physical properties 7. In addition 
to the coating, carbon-based yolk-shell magnetic nanoparticles (CYSMNPs) will be 
functionalized with nitric acid, the resultant CYSMNPs becoming negatively charged 
and enabling them to have great affinity with cationic drugs, such as Doxorubicin and 
Omeprazole. The electronic affinity between the CYSMNPs and the drugs can be 
different in solutions with different pH. Such difference can facilitate both the drug 
loading and the drug release depending on the solution that will be used. However, due 
to this behavior, it is possible to study the optimization of the magnetic core production, 
coating and functionalization efficiency and the drug loading and release environment, 
focusing on the release of higher amount of drugs, simulating different conditions of the 
human body.  
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1.1 Objectives 
 The main objectives of this dissertation are the development and 
functionalization of magnetic nanostructures coated with carbon materials with high 
potential for the controlled release of drugs. The magnetic core is developed by two 
approaches of Solution Combustion Synthesis (SCS). In the first approach, the synthesis 
of the magnetic nanoparticles is done by the reduction of Fe (III) using citric acid. In the 
second approach, a green route is considered, using extracts of tangerine peel with high 
reducing power for the reduction of Fe (III). After the NPs synthesis and 
functionalization, the materials are applied in controlled drug release tests, using 
Doxorubicin (DOX) and Omeprazole (OME) as model drugs, under different 
conditions, mainly altering the pH of the medium in the range 4.0-7.4. Controlling the 
pH of the medium allow the drug to avoid side effects on normal cells. 
 
  
 
 
 
 
 
 
Chapter 2: State of the Art
Chapter 2: State of the Art 
5 
 
2 State of the Art 
2.1 Magnetic Nanoparticles  
 Magnetic nanoparticles are systems formed by grains in the order of nanometers 
(10 -9 m) and, due to its molecular and atomic state, they have physical and chemical 
properties quite different from those observed in bulky materials. The formation of magnetic 
monodomes, the existence of a large surface area in relation to the volume and the possibility 
to coat the nanoparticles with various types of specific binders, are some of the characteristics 
responsible for making MNPs potentially important in technological applications 8,9. 
 During the past decade, researchers have shown an increased interest in 
multifunctional nanomaterials. Analyzing the statistics at the Scopus database of the 
publications about “magnetic nanoparticles” over the last 10 years, more than 50 000 papers 
have been published. According to the Web of Science database, the number of citations per 
year has been linearly increasing, reaching 9 717 citations last year. MNPs have been one of 
the most attractive types of nanomaterials used in different fields 10. The biomedical 
applications of MNPs have become prominent topics for researchers in the modern century. 
These applications include drug delivery, magnetic resonance imaging (MRI) and magnetic 
hyperthermia treatment, among others 11–13. Also, MNPs can be very useful for environmental 
protection applications, water treatment, environmental remediation, 
biotechnology/biomedicine, magnetic recording media, electromagnetic wave absorption and 
magnetic sensors 2,14,15. 
 Two key issues dominate the magnetic properties of nanoparticles: finite‐size effects 
and surface effects, which give rise to various special features 16.  They also exhibit a lot of 
important features, such as high specific surface area, chemical stability, low intraparticle 
diffusion rate, high loading capacity and superparamagnetism 17,18. The performance of the 
magnetic materials is classified based on their response to an external magnetic field 7. The 
magnetism can be categorized in three basic types: diamagnetism, paramagnetism and 
ferromagnetism 1. 
 Magnetic nanoparticles prepared from iron oxide are considered attractive due to their 
multifunctional characteristics, including small size, supermagnetism and low toxicity. They 
are responsive to the application of a magnetic field 19,20 and, in this way, the substances to 
which they are complexed can be manipulated and transported 19. 
Chapter 2: State of the Art 
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 The main challenge when using magnetic nanoparticles is the agglomeration of the 
nanoparticles when they are subjected to an internal or external magnetic field. In order to 
overcome that inconvenience, it has been necessary to coat the magnetic nanoparticles with an 
inert shell, which modify their surface properties and prevent direct contact between them. 
Magnetic nanoparticles coated with a polymer or an inorganic nanostructure have been widely 
studied because of their unique properties 21,22. 
 
2.2 Iron Oxides 
 Hematite (α-Fe2O3), magnetite (Fe3O4) and maghemite (γ- Fe2O3) are three of the most 
important iron oxides used in various technological applications 23,24. In particular, magnetite 
and maghemite possess some physicochemical properties such as low toxicity, 
biocompatibility and high surface area, making them convenient for applications in several 
areas including catalysis/photocatalysis, magnetic storage media, magnetic fluids, 
biomedicine or electrochemical applications 23,25,26. 
 Comparing all kinds of magnetic oxides, magnetite nanoparticles (MagN) are 
considered as the most promising, due to its excellent magnetic properties. This is notably 
important in biomedical applications, since the materials demand a high standard of stability 
and nontoxicity in addition to hydrophilic properties 14. Magnetite and magnetite colloids 
have low toxicity, good biocompatibility and tunable magnetic properties. Fe3O4 
microcrystals have different morphologies depending on the pH values of the precursor 
solution 27. 
 Another interesting property of magnetite is its superparamagnetic behavior, i.e. the 
capacity of the nanoparticles to become strongly magnetic in the presence of a magnetic field 
and, when the field is removed, to become immediately re-dispersed in solution, because do 
not show any residual magnetism 28.  
 
2.3 Nanocomposites 
 Nanocomposites (NCs) are multi-phasic materials with a matrix material that 
incorporates units with at least one dimension in the size range below 100 nm, resulting in 
novel functional materials 29. The characteristics of nanocomposites depends on its constituent 
materials, size, structure and formation, and it can exhibit different properties from its 
Chapter 2: State of the Art 
7 
 
individual constituent materials and also from its bulk form 30. Nanocomposite structures 
containing metals and semiconductors are expected to have important practical applications 
due to the fact that they exhibit surface plasmonic and excitonic resonance 31,32.  
 One of the major challenges in the synthesis of nanocomposites is how to produce the 
desired structure with various functions such as catalytic, magnetic, electronic and optical 
properties, as well as surface functionality coupled with biocompatibility, low toxicity and 
high stability. Magnetic nanocomposites with magnetic cores and functional shells have 
drawn the attention because of their unique functionality and separability 33. 
 The use of coatings, like polymers, silica, carbon or other materials, over the magnetic 
particles can stabilize them, preventing aggregation and functionalizing the MNPs to extend 
their applications 34. Nowadays, nanocomposites are employed in multiple technological 
fields, such as electronics, optics, medical fields, materials modification and many other 
fields 29,31. 
 
2.4 Methods of Synthesis 
 There have been impressive developments in the field of nanotechnology with 
numerous methodologies formulated to synthesize nanoparticles 6. There are some popular 
ways to achieve shape-controllable, monodisperse and highly stable MNPs, such as solution 
combustion synthesis, co-precipitation, hydrothermal synthesis, thermal decomposition, 
microemulsion, sonolysis and biosynthesis 17 .  
 Co-precipitation is a facile and convenient way to synthesize iron oxides from aqueous 
Fe2+/Fe3+ solutions, by the addition of a base at room temperature or at an elevated 
temperature. The size and shape of the magnetic nanoparticles depends very much on the type 
of salts used 16,17,35.  
 Magnetic nanocrystals can essentially be synthesized through the thermal 
decomposition of organometallic compounds, such as metalacetylacetonates, metal 
cupferronates or carbonyls, in high-boiling organic solvents containing stabilizing surfactants. 
Fatty acids, oleic acid, and hexadecylamine are often used as surfactants. The shape and size 
of the nanoparticles depend on the proportion of organometallic precursors, surfactants and 
solvents 16,17.  
Chapter 2: State of the Art 
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 Microemulsions are isotropic, thermodynamically stable and colloidal dispersions, 
consisting of at least three components: a non-polar phase, a polar phase and a surfactant 36. In 
this method, the hydrocarbon phase is continuous and the aqueous phase is dispersed as 
microsphere, which is surrounded by the singer-layer surfactant molecules. The size of the 
reverse micelle depends on the molar ratio of surfactant to water. Using the microemulsion 
technique, metallic cobalt, cobalt/platinum alloys and gold-coated cobalt/platinum 
nanoparticles have been synthesized in reverse micelles of cetyltrimethlyammonium bromide, 
using 1-butanol as the cosurfactant and octane as the oil phase 16,17. 
 The hydrothermal synthesis is usually applied in aqueous media in reaction kettles at 
high pressure and high temperature, involving the hydrolysis and condensation of the metal 
salt, in the presence of water, to produce ultrafine metal oxides or metal particles, with 
magnetic properties 37. Hydrothermal processing is one of the successful ways to grow 
crystals of many different materials. This technique has also been used to grow dislocation 
free single crystal particles and grains formed in this process could have a better crystallinity 
than those from other processes 16,17,35 
 For the sonolysis method, new structures can be produced through high intensity 
ultrasound, and it has no need for high pressure, high temperature or long time of reaction, 
which make it an unusual route. The sonolysis technique involves passing sound waves of 
fixed frequency through a slurry or solution of carefully selected metal complex precursors 38. 
As a result, the sonolysis method is usually applied to achieve different types of bare and 
functionalized nanoparticles 17,35. 
 Biosynthesis involve the use of green technology, such as crude extracts from plants, 
that are responsible for the reduction process of metal ions in the redox reaction to obtain 
nano-sized nontoxic particles. The exact mechanism of the biosynthesis has not been 
explained clearly, and the shape and size of the nanoparticles can’t be controlled 
precisely 17,39,40.  
 
2.4.1 Solution Combustion Synthesis 
Among the soft chemical methods, the SCS is an efficient method for the preparation 
of oxide materials. Moreover, it is considered as a potential route for the preparation of iron 
oxide composites. It is essentially a self-sustained exothermic redox reaction between an 
oxidizer and a fuel in a homogenous aqueous solution. Usually, oxidants are metal precursors 
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themselves, like for example metal nitrates, sulfates and carbonates, and the fuel is any 
organic material, as for example citric acid, urea and glycine 2,41. Among various metal salts, 
hydrated nitrates are preferred as metal precursors, because of the efficient oxidizing power of 
NO3 − groups, and their lower decomposition temperature and good solubility in water 41. 
Basically, the SCS consists of three main steps, specifically the formation of the combustion 
mixture, the formation of the gel and the combustion of the gel 4. 
 The main advantage of the SCS is its time- and energy-efficiency, with low costs of 
the raw materials, simplicity, short reaction time and low energy consumption of the synthesis 
method 4,23,41. In addition to these advantages, the SCS only needs simple and low cost 
instrumentation that can be easily scaled up, and it has the possibility to obtain products with 
diverse functionality and structures 41. 
The final products obtained through SCS are materials with high purity, high surface 
area, optimum agglomeration, high adsorption capacity for both anionic and cationic dyes, 
short time to reach equilibrium, good potential of regeneration and reuse and environmentally 
friendly 4,23,42. 
 
2.4.2 Solution Combustion Synthesis with plant extracts 
 The conventional way to synthesize Iron Nanoparticles (FeNps) use a variety of 
organic solvents and reducing agents like sodium borohydride (NaBH4), hydrazine and 
sodium dodecyl sulphate, among others 43. These reducing agents can cause risks to the 
environment and can create harmful by-products to human health 44. Green synthesis is an 
alternative way to synthesize MNPs. Normally, this type of synthesis is made by adding only 
plant extracts in a solution containing Fe(III) and/or Fe(II) 45. The nanoparticles synthesized 
using such green technologies have diverse natures, with higher stability and appropriate 
dimensions 46. 
 The use of plant extracts gives the possibility to prepare magnetic nanostructured 
materials via several chemical routes, using benign reagents, thus reducing the risk of using 
dangerous substances 47. For the SCS, the plant extracts will act like a fuel in the chemical 
reaction 5. This approach for the SCS, can influence the nanoparticles that are produced, like 
their size, shape and morphology. In addition, this method also generates nanoparticles with 
high dispersibility and high stability 47. 
Chapter 2: State of the Art 
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2.5 Structure of Nanocomposites 
 Depending on the type of synthesis used, the composition and their purpose, the 
structure of nanocomposites can change from each other 7. Based on their form, the 
nanocomposites can be divided in distinguished categories, as solid nanoparticles, Janus 
particles, hollow particles, core–shell (CS) particles and reverse bumpy balls and yolk-shell 
(YS) particles 48. Figure 1 show those types of structure. 
 
 
Figure 1 - Transmission Electron Microscopy (TEM) images and schematic representations of the common 
types of nanostructures: a) Solid nanoparticle, b) Hollow particle, c) Janus particle, d) Core-shell particle, e) 
Reverse bumpy balls and f) Yolk-shell particle 48. 
 
It is important to know the differences between those types of nanostructures. Solid 
nanoparticles are composed by one or many elements, but with a uniform structure. In Janus 
particles, the two parts of the particle have different chemical or physical properties. The 
Hollow particles have an empty interior. The core-shell type have comprising smaller solid 
particle(s) coated with a tight layer of other element(s), as well as from reverse Bumpy balls 
which have encapsulated cores attached to the shell 48. 
 Sometimes, issues of biocompatibility and toxicity limit the choice of the materials. 
However, the use of coatings may make the use of these materials feasible. This process also 
decrease the agglomeration of particles 1. The coating can be polymeric or based on activated 
carbon, silica and gold, among other materials. The coating can be separated in two 
categories: organic components coating and the inorganic components coating. The organics 
include polymers and surfactants that can be added to the surface of the nanoparticles during 
Chapter 2: State of the Art 
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or after the synthesis to avoid aggregation. The inorganics includes carbon, silica, precious 
metals or oxides. Carbon coatings are used to protect magnetic nanoparticles because this type 
of coating materials have higher thermal stability and higher biocompatibility than polymers 
or silica. The most applied coated structures are core-shell and yolk-shell 17,29,30. Also, the use 
of some reagents in the synthesis of the coating, as Tetraethyl Orthosilicate (TEOS), helps to 
control the distribution of MNPs. The surface coating of MNPs  is carried out to control the 
size, the shape, the dispersibility of the nanoparticles in the solvent and to develop the 
effective protections to maintain the stability of the nanoparticles 49. In this case, TEOS was 
chosen in this work, since it hydrolyses in the presence of water, generating silanol groups 
(Si-OH) that polymerize to form siloxane bonds (Si-O-Si) and ultimately inducing the 
precipitation of a silica gel 50. In addition, the shell can be constituted by multiple layers and 
contain functional groups or targeting moieties 48. For this work, it was chosen to coat the 
MNPs by polymerization of resorcinol and formaldehyde (RF). 
In a first step of the coating process, silica spheres are produced. Ammonia is used to 
prevent the particles aggregation and to allow the formation of a stable colloidal suspension. 
In parallel to the formation of the silica spheres a slower reaction occurs between resorcinol 
and formaldehyde catalyzed by OH- ions. Condensation between these species will occur 
within the nanospace surrounding the silica particles resulting in the formation of a RF 
polymeric layer around the silica spheres. To produce the carbon coating, the nanoparticles 
are then heated in nitrogen atmosphere to convert the RF polymeric layer into carbon. 
Subsequently, the carbonized product formed is washed with sodium hydroxide to dissolve 
the silica core 51. 
Normally, after the coating process, the shell is functionalized for a best performance in 
the desired application. This functionalization can be made using Pluronic-127. The use of 
Pluronic F-127 aims to enhance the colloidal stabilization and biocompatibility of the 
GYSMNPs 52. 
 
2.5.1 Core shell 
 Core-shell nanoparticles (CSNPs) are a class of particles containing a core and a shell. 
The core and the shell can be different materials or the same materials with different 
structures. The core may be a single sphere or an aggregation of several small spheres. The 
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shell structure can be a continuous layer or the attachment of smaller spheres onto a bigger 
core sphere or aggregated core spheres 53.  
 The process to synthesize core–shell particles are usually a two-step or a multiple-step 
process. The core is synthesized first and the shell is then formed on the core particle via 
different methods, depending on the type of core and shell materials and on their 
morphologies 53. The motivation in the preparation of core-shell particles is to combine the 
desired properties of different materials and structures in order to offer simultaneous effects, 
to stabilize the active particles or to provide biocompatible properties 7. 
 In the case of magnetic nanocomposites with core-shell structures, their magnetic 
properties are sometimes restrained to a specific range, since the core materials are easily and 
compactly encapsulated in the shell material 13. 
 
2.5.2 Yolk shell 
 The yolk-shell nanoparticles (YSNPs) represent a new class of special core-shell 
structures with a distinctive core@void@shell configuration, generally denoted as A@B 54.  
The main difference between the CSNPs and the YSNPs is the presence of a void space 
derived from the sacrificial layer, which gives rise to multifunctional and other unique 
properties of YSNPs 7. The YSNPs are defined as hybrid structures (mixture of core/shell and 
hollow) where a core particle is encapsulated inside the hollow shell and may move freely 
inside the shell. For that reason, they are also termed as movable core/shell or rattle-type 
nanostructures 55. 
 YSNPs are functional nanomaterials with multiple applications, such as catalysis, 
nanoreactors, drug/gene delivery, lithium-ion batteries and biosensors, achieved due to their 
tailorability and functionality in both the cores and hollow shells 54. So far, researchers have 
synthesized four types of yolk-shell nanoparticles, specifically those with single cores, 
multiple cores, multiple shells and raspberry-like cores 13.  
 According to the core and shell morphologies, YSNPs can be classified into 
‘spherical’ and ‘non-spherical’ structures. The spherical structures have the core and the shell 
in a spherical shape, and in the ‘non-spherical’ structure at least one structure should be non-
spherical 55.  
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 The synthesis of YSNP  usually involves several steps including the fabrication of the 
core, the growth of the shell, as well as various post‐synthesis treatments, such as core 
removal, functionalization of compartments and loading with cargo 48. Commonly, the 
synthesis starts with the formation of the core (or yolk) of the structure, followed by coating 
with the desired material according to the application of the synthesized NPs 7.  
 
2.6 Applications  
 Magnetic nanoparticles are of great interest for a wide range of areas, such as catalysis 
applications, industrial applications, drug delivery, bioseparation, environmental applications 
and magnetic hyperthermia treatment. There are still a wider range of applications for the 
magnetic nanoparticles, which requires advances in the techniques in order to produce 
nanoparticles with specific sizes and well controlled magnetic properties. The application of 
magnetic nanoparticles also highly depends on the stability of the particles 16,20. 
 
2.6.1 Industrial Applications  
 Magnetic iron oxides are commonly used as synthetic pigments in paints, ceramics 
and porcelain, because they display a range of colors with pure hues and high tinting 
strength 24. Magnetite and hematite have been used as catalysts for a number of industrially 
important reactions, including the synthesis of NH3. They can also be applied in many areas 
including high density magnetic data storage devices, magnetic information storage, 
xerography, electronics (recording media), catalysis, magnetic inks (for jet printing) and 
magnetic refrigeration and their systems, among others 35,56,57. 
 
2.6.2 Bioseparation 
 In biomedical research, the separation of specific biological entities from their native 
environment is sometimes required. Superparamagnetic colloids are ideal for this application 
due to their on-off nature of magnetization, with and without an external magnetic field, 
enabling the transportation of biomaterials with a magnetic field 35. Magnetic nanoparticles 
have been extensively used for separation and purification of cells and biomolecules in 
bioprocesses 35,58,59. 
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2.6.3 Drug Delivery 
 The possibilities for the application of magnetic nanoparticles in drug targeting have 
drastically increased in the last few years 16. MNPs, in combination with an external magnetic 
field and/or magnetizable implants, allow the delivery of particles to the desired target area 
and their fixation at the local site, while the medication is released and acts locally. In other 
words, the magnetic particles first acts as carriers of the drug, which is attached to its outer 
surface. Once the drug-coated particles have been introduced into the bloodstream of the 
patient, a magnetic field gradient is used to guide the particles to the targeted region. This 
kind of treatment can eliminate side effects and also reduce the required dosage 35,60. 
 
2.6.4 Catalysis Applications 
 The recovery of catalysts in a liquid-phase reaction can be much easier using a 
magnetically driven separation, when compared to a cross flow filtration and centrifugation, 
especially when the catalysts are in the sub-micrometer size range. In terms of recycling 
expensive catalysts or ligands, immobilization of these active species on MNPs leads to the 
easy separation of catalysts in a quasi-homogeneous system 16,35. Magnetic nanoparticles with 
core–shell structure may enable the development of a new type of catalysts, in which the shell 
consists of the catalytically active species, and the magnetic core can act as anchor to separate 
and recycle the catalyst 16. 
 
2.6.5 Environmental Applications 
 For environmental applications, nanotechnology offers the potential of novel 
functional materials, processes and devices with unique activity toward recalcitrant 
contaminants, enhanced mobility in environmental media and desired application flexibility 
61. Iron NPs technology is considered to be among the first generation of nanoscale 
environmental technologies, which could provide cost-effective solutions to some of the most 
challenging environmental cleanup problems 35,62. Extensive laboratory studies have 
demonstrated that nanoscale iron particles are effective for the transformation of a wide array 
of common environmental contaminants, such as chlorinated organic solvents, organochlorine 
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pesticides, PCBs, organic dyes, various inorganic compounds and metal ions such as As(III), 
Pb(II), Cu(II), Ni(II) and Cr(VI) 61. 
 
2.6.6 Magnetic hyperthermia Treatment 
 Another interesting application of magnetic nanoparticles is in magnetic hyperthermia 
treatment, as a supplementary treatment to chemotherapy and radiotherapy. Magnetic 
hyperthermia employs magnetic nanoparticles as heat sources to raise tissue temperature 
to ~43°C, based on the fact that when magnetic nanoparticles are exposed to a varying 
magnetic field, heat is generated by the magnetic hysteresis loss, at which tumors cells are 
known to be more sensitive to heat than healthy cells. The localization of the MNPs is 
obviously critical to the success of hyperthermia as the objective is to spare the surrounding 
healthy tissue from excessive heat 16,17,20. 
 
2.6.7 Magnetic Resonance Imaging 
 Magnetic nanoparticles have been studied as contrast agents in magnetic 
resonance imaging (MRI) for very promising applications, such as tumor imaging, cell 
labelling and tissue engineering 63,64. Magnetite iron oxide nanoparticles are the most 
commonly used negative MRI contrast agents due to their magnetism, low toxicity and 
good biocompatibility compared to other MNPs (such as MnFe2O4 and ZnFe2O4). 
Nevertheless, specific narrow size distribution, superparamagnetic behavior and surface 
modification are needed properties in the nanoparticles for this application 65. 
 
2.7 Drug Delivery 
 Targeted drug delivery to specific body parts has become one of the important 
ventures of today’s world, as conventional dosage forms are generally associated with 
difficulties in approaching the target site with a specified dose after or during a proper time 
period. As a result, the development and evaluation of novel drug delivery systems has 
become more demanding in recent years 66. The use of nanotechnology for this purpose has 
been promising, given the side effects of treatments such as chemotherapy and radiotherapy 
and the risks of surgeries for the patients 7. NPs with diameters ranging from 10 to 200 nm 
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present promising pharmacokinetic features. Drug encapsulated NPs accumulate both passive 
and active mechanisms for extended and complete circulation periods, continuous drug 
discharge kinetics and recovery of tissues from tumor 67. 
 Nanotechnology is an emerging field of research that plays a key role in medicine, 
particularly in the formulation and delivery of drugs at pathological sites with increased 
success. The discovery of non-biodegradable NPs, including magnetic NPs, as coating agents 
in nano-drug delivery, has improved delivery at lower doses and increased aqueous solubility 
and bioavailability of the drug with reduced side effects. NPs can also increase a drug’s 
circulation half-life period with advanced pharmacokinetics 68,69. 
 There are some important nanoparticle characteristics for drug delivery, such as 
particle size, surface properties of the nanoparticles, drug loading and drug release. Particle 
size and size distribution are the most important characteristics of nanoparticles, since they 
can influence drug loading, drug release and the stability of the nanoparticles. For example, 
smaller particles have a larger surface area-to-volume ratio; therefore, most of the drug 
associated with small particles would be at or near the particle surface, leading to faster drug 
release 70–72. 
 A successful nano-particulate delivery system should have a high drug-loading 
capacity, thereby reducing the quantity of matrix materials for administration. A drug can be 
loaded into the nanoparticle system by the following two methods: (i) drug integration during 
the process of production of the nanoparticles or (ii) drug adsorption after the synthesis of the 
nanoparticles. Additionally, it is important to consider both drug release and polymer 
biodegradation when developing a nano-particulate delivery system 72,73. In this work, the 
drugs will be loaded after the synthesis of the nanostructures, since in the second step of the 
coating process the nanostructures are subjected to high temperatures, which could damage 
the dug. 
 Thus, the advantages of using nanoparticles for drug delivery are a result of main basic 
properties, due to their small size, enabling extravasation through the endothelium in 
inflammatory sites, epithelium and tumors or penetration in micro capillaries. Nanoparticles 
also have as advantage over larger micro particles the fact that they are better suited for 
intravenous delivery 72. Also, they have an easy manipulation of particle size and its surface 
characteristics to achieve drug targeting, controlled and sustained discharge of the drug, both 
during the transportation and at the target site, high drug loading capacity, usage of various 
routes of administration, including parenteral, intra-ocular, oral, nasal etc. Efficient curcumin 
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delivery using nanotechnology, not only helps to overcome solubility, rapid drug metabolism, 
degradation and drug stability issues, but also should diffuse or target indent tissues while 
minimizing unintended toxicity to surrounding normal cells/tissues 69. To achieve an increase 
of success in drug targeting, NPs can be coated with polymers, metals or non-metals 72. 
 Omeprazole is a synthetic molecule (345 Da) and a member of the group of 
pharmacological proton pump retardants, which play an essential role in controlling stomach 
acid production in humans by suppressing the proton pump in the stomach. It also has 
hormone-like functions that modulate natural hormone-signaling networks 74,75. The chemical 
structure of Omeprazole is shown in Figure 2. 
 
 
Figure 2- Chemical structure of Omeprazole 76 
 
 Omeprazole is widely used in the treatment of active duodenal ulcer, active benign 
gastric ulcer, gastro-oesophageal reflux disease, erosive oesophagitis and other pathological 
hypersecretory conditions, such as Zollinger-Ellison syndrome 77. Omeprazole is also very 
sensitive to light, heat, moisture, solvents and exposure to various salts and metal ions, which 
make it an excellent candidate as a worst-case study to develop multiple-coated particles 77,78.  
 Doxorubicin (DOX) is an anthracycline antiblastic antibiotic isolated from cultures of 
Streptomyces peucetius var. caesius. The chemical structure of DOX is shown in Figure 3. It 
is soluble in water for injections and in physiological saline solution 7. Doxorubicin has been 
used in oncologic practice since the late 1960s. It held promise as a powerful drug in the fight 
against cancer, regression in various neoplasms, such as breast cancer, lung, bladder, thyroid 
and ovary carcinoma, soft tissue sarcoma and bone sarcoma, Hodgkin's and non-Hodgkin's 
lymphomas, neuroblastoma, Wilms' tumor, acute lymphoblastic leukemia and acute 
myeloblastic leukemia 79,80.  
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Figure 3 - Chemical structure of Doxorubicin 81 
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3 Methodology 
 
3.1 Reagents 
 For the synthesis of the magnetic core, a solution with iron (III) nitrate 
nonahydrate (Sigma-Aldrich, Germany) was used as iron source for magnetite 
formation and citric acid monohydrate (98.8%, WWR Chemicals, Belgium) and 
tangerine extract as the fuel of the SCS reaction. In the early stages of the coating 
reaction, the previously synthesized MNPs were dispersed in absolute ethanol (Carlo 
Erba, France) and distilled water, and the hydrolysis and condensation polymerization 
of TEOS (98% Fluka Chemika, Germany) was favored. Subsequently, as the reaction 
progressed and the TEOS hydrolysis and polymerization processes approached 
completion, the polymerization of resorcinol (99%, Fisher Scientific, U.K.) and 
formaldehyde (37-38% p/p, Panreac, Spain) became the predominant process, resulting 
in the formation of a phenolic resin polymer layer. To remove the silica, a sodium 
hydroxide solution (99.1 %, Fisher Scientific, U.K.) was used. The phosphate buffer 
solutions employed for drug loading and release were prepared with potassium 
dihydrogen phosphate (V.P., Portugal), disodium hydrogen phosphate 12-hydrate 
(Pronalab, Portugal), and sodium dihydrogen phosphate hydrate (Pronalab, Portugal). 
 
3.2 Synthesis of functionalized carbon-coated magnetic nanoparticles 
 For a better understanding, the entire process can be divided in the following 
steps: 
Step 1 – Synthesis of magnetite: 
 1.1 – SCS with citric acid. 
 1.2 – SCS with tangerine extract 
Step 2 – Coating and carbonization under a N2 atmosphere 
Step 3 – Silica removal (etching) 
Step 4 – Chemical treatment with nitric acid (HNO3) 1 M 
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Step 5 – Functionalization with Pluronic F- 127 
 
3.2.1 Synthesis of the magnetic core  
 The methodology to produce the magnetic core chosen in this work was the 
SCS, using iron (III) nitrate nonehydrate (Fe(NO3)3·9H2O) as the oxidizer and citric 
acid (C6H8O7) as the fuel of the reaction, as shown in the reaction Equation 1. 
 
                (1) 
 
 3.2.1.1 Production with citric acid  
The magnetic core was synthesized using approximately 5.234 g of iron III 
nitrate nonahydrate (Fe(NO3)3.·9H2O), solubilized in 10 mL of distilled water in a 
250 mL round bottom flask, to which 2.3198 g of citric acid (C6H8O7), also solubilized 
in 10 mL of distilled water, was added dropwise using a peristaltic pump ISM 845, 
ISMATEC (Figure I - Annex A). The solution was heated at 80 °C in a drying oven, 
Binder FD 115 (Figure II- Annex A), for 6.5 h. The flask was placed in an oil bath 
heated by a magnetic stirring plate (IKA® C-MAG HS 7, Figure III - Annex A) and 
submitted to a flow of N2 (100 Ncm
3.min-1) for 1 h at 25 °C to ensure an inert 
atmosphere therein. After this time, the solution was heated to 180 °C for 3 h. Then, the 
product obtained was washed with distilled water until neutral pH, by centrifugation at 
600 rpm during 5 minutes in a MPW- 260R centrifuge, MPW Med. Instruments 
(Figure IV - Annex A). The resultant material was dried in oven overnight at 60 °C. 
  
3.2.1.2 Production with tangerine extract  
For the production of the extract, peels of tangerines were used. The peels were 
dried by exposition to sun  for 72 h and then placed in oven at a temperature of 100 °C 
for approximately 18 h. After drying, the peels were ground in an analytical mill, IKA 
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A11 basic (Figure V - Annex A) and particles with diameters between 250 and 106 μm 
were selected with sieves and stored in vial until their use. 
The extract was obtained mixing 10 g of peels in 65 mL of distilled water under 
vigorous stirring in a 250 mL round bottom flask immersed in an oil bath at room 
temperature for 3 h. Then, the flask was heated at 60 °C for 1 h and the dispersion was 
centrifuged to separate the grinded peels of tangerine from the supernatant at 6000 rpm 
for 10 min. Finally, the extract solution obtained was stored in freezer until its use.  
The magnetic core (magnetite) was synthesized using approximately 5.234 g of 
iron III nitrate nonahydrate (Fe(NO3)3.·9H2O), solubilized in 10 mL of distilled water in 
a 250 mL round bottom flask. Then, about 7 mL of the tangerine extract were added 
dropwise. The solution was placed into the drying oven at 80 °C for 6.5 h. The flask was 
then placed in an oil bath on a magnetic stirring plate and submitted to a flow of  N2 for 
1 h at 25 °C to ensure an inert atmosphere therein. Later, the solution was heated at 
180 °C for 3 h. After this procedure, the product obtained was washed with distilled 
water to neutral pH, by centrifugation at 600 rpm during 5 minutes. The resultant 
material was dried in oven overnight at 60 °C. 
  
3.2.2 Coating process  
The coating process of the magnetic nanoparticles is illustrated in Figure 4. 
 
 
Figure 4 - Coating process of the magnetic nanoparticles. 
 
For the coating, a mass of approximately 0.25 g of nanoparticles was measured 
and placed into a 250 mL erlenmeyer flask, containing 150 mL of absolute ethanol and 
50 mL of distilled water. The solution was placed in an ultrasonic bath, Ultrasons-H, P-
30 °C for 1 hour 30 °C for 6 hours 80 °C for 8 
hours 
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 Selecta (Figure VI - Annex A),  at room temperature, until all the magnetite particles 
were dispersed in the medium 52.  
The dispersion was transferred to a 500 mL round bottom flask, which contained 
0.100 g of Resorcinol and 1.4 mL of a 25% ammonia solution. The flask was placed in 
an oil bath and stirred with a magnetic stirrer at 30 °C for 1 h. Subsequently, 210 μL of 
TEOS and 150 μL of formaldehyde (37-40%) were added dropwise and stirred for 6 h at 
30 °C. After that time, the temperature was raised to 80 °C and the flask remained at this 
temperature for 8 h 52. The resulting polymer-coated nanoparticles was washed with 
distilled water until neutral pH, using a centrifuge (6000 rpm for 5 min) and finally with 
absolute ethanol. The resultant material was then dried overnight and subsequently 
weighted and stored in vial.  
At the second step of the coating process, the polymer-coated nanoparticles was 
carbonized under a N2 atmosphere in a vertical tubular furnace (ROS 50/250/12, 
Thermoconcept, Figure VII- Annex A).  The gas phase thermal treatment under a N2 
flow (100 Ncm3.min-1) was conducted at 120 °C and 400 °C during 1 h at each 
temperature and then at 600 °C for 4 h using heating rates, in each case, of 2 °C.min-1. 
The resultant carbon-coated MNPs were denoted as Fe3O4@SiO2.C 
45,52 .  
 
3.2.3 Silica etching  
 Fe3O4@SiO2.C nanoparticles were etched under stirring with a sodium 
hydroxide solution 10 M. 10 mg of nanoparticles was added to 1 mL of the NaOH 
solution. The Erlenmeyer, containing the suspension, was placed on a magnetic stirrer 
and left under vigorous magnetic stirring for 16 h 45,52. The resulting material was 
washed with distilled water to neutral pH using a centrifuge (6000 rpm for 5 min) and 
then washed with absolute ethanol. The material was dried overnight at 60 ºC in oven, 
resulting in the yolk carbon shell magnetic nanoparticles (YCSMNP). After drying the 
sample was weighted and stored in vial.  
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3.2.4 Chemical treatment  
The colloidal stabilization of the YCSMNPs was increased by a chemical 
treatment with acid, incorporating carboxylic and hydroxyl groups, without 
compromising the magnetic core. The YCSMNPs were suspended in a HNO3 solution 
(1 M) with a ratio of 5 mg of YCSMNPs per 1 mL of HNO3 solution. The flask 
containing that suspension was placed in a oil bath at 65 °C with magnetic stirring for 
3 h 45,52. Subsequently, the resulting material was washed with distilled water until 
neutral pH using a centrifuge (6000 rpm for 5 min) and then washed with absolute 
ethanol. The material was further dried at 60 ºC in oven overnight. After drying it was 
weighted and stored in vial. 
 
3.2.5 Funcionalization with pluronic F-127 
  After performing the chemical treatment, the resulting material was 
functionalized with Pluronic F-127 (PF127). For this purpose, a mass of 
approximately 40 mg of the chemical treated YCSMNP was measured and dispersed in 
20 mL of distilled water with ultrasounds. Then, 800 mg of PF127 was added and 
magnetically stirred for 5 h at room temperature 52. The resulting solution was washed 
by centrifugation (13 000 rpm, 20 min) with distilled water to remove unbounded 
copolymer and the resulting material was dried in oven at 60 °C for 8 h, resulting in the 
functionalized sample FYCSMNP. 
 
3.3 Characterization 
The magnetic core was characterized by X-ray diffraction (XRD) in order to 
perform phase identification and to determine the crystalline structure and the total core 
size. XRD analysis was performed in a PANalytical X’Pert MPD equipped with a 
X’Celerator detector and a secondary monochromator (Cu Kα λ= 0.154 nm; data 
recorded at a 0.017° step size). The composition of magnetite present was identified 
using HighScore software and Crystallography Open Database. Crystallite sizes were 
determined by the Halder–Wagner method 82. The effects of the functionalization were 
analyzed using the spectral analysis in the Fourier transform infrared spectrometer (FT -
 IR), in a PerkinElmer equipment.  
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3.4 Drug loading and release 
Phosphate buffer solutions (PBS) with different pH were used for the drug 
loading and release tests. These solutions were prepared as following: a) PBS pH 4.5: 
3.40 g of dihydrogen potassium phosphate was diluted in 0.5 L of distilled water; b) 
PBS pH 6.0: 24.6 mL of Na2HPO4·12H2O (0.2 M) solution was mixed with 175.4 mL 
of NaH2PO4ּ·H2O (0.2 M) solution; c) PBS pH 7.4: 95 mL of of NaH2PO4·H2O (0.2 M) 
was mixed with 405 mL of Na2HPO4·12H2O (0.2 M) solution. 
 
3.4.1 Drug loading  
For the DOX loading, a solution of 1000 μg.mL-1 was used. To produce this 
solution, a mass of 25 mg of DOX was weighted and dissolved in 5 mL of distilled 
water. 4 mL of this solution was further diluted in 20 mL of PBS (pH 7.4) solution.  
After that, 20 mg of the FYCSMNP was measured and dissolved in 20 mL of PB (7.4) 
solution with the aid of ultrasound until the solutions were homogeneous.  
For the OME loading, a solution of 250 μg.mL-1 was used. To produce this 
solution a mass of 12.5 mg of the drug was measured and dissolved in 50 mL of 
distilled water. 12.5 mg of FYCSMNP were then added to the solution.  
 The drug loading was conducted by mixing the solution of the FYCSMNP and 
the drug solution under agitation in a IKA® KS 130 basic orbital shaker 
(Figure VIII -Annex A), for 48 h, at room temperature 7. Then, the resulting suspension 
was centrifuged (6000 rpm for 5 min) and the bottom body containing the drug loaded 
FYCSMNP lyophilized and stored in a freezer until its use. The supernatant was taken 
to analyze by the T70 UV-VIS spectrophotometer, PG Instruments Ltd. 
(Figure IX -Annex A) for determination of DLC and DLE, at 480 nm for the DOX and 
300 nm for the OME, as follow: 
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Where, CDRUG-FYCSMNPs is the concentration of drug (DOX and OME) loaded in 
the FYCSMNPs (μg.mg-1), CFYCSMNPs is the concentration of FYCSMNPs, C0Drug is the 
initial concentration of the drugs solution before the loading (μg.mL-1), Cf DRUG is the 
final concentration of the drugs measured in supernatant after the loading (μg.mL-1). 
The concentration of drug loaded in the FYCSMNPs is measured by subtracting the 
concentration of the drug in the supernatant from the initial concentration of the drug 
solution. These concentrations were calculated using the calibration curves shown in 
Figure 5. 
 
 
Figure 5- Calibration curves for determination of DOX and OME concentrations by UV-Vis 
spectrophotometry. 
 
3.4.2 Drug release 
The release tests were carried out in duplicate for different solutions of PBS at 
physiological (pH 7.4) and acidic pH levels (pH 4.5 and   6.0). To perform the release of 
the drug, masses between 1 mg and 2 mg of nanoparticles lyophilized with the drug 
were measured and then added to 10 mL of buffer solutions at different pHs. The 
solutions were homogenized with  ultrasonic bath.  
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The flasks were placed in a orbital shaker and maintained in oven at 37 °C 
(human body temperature) under constant stirring during the release test. The mixture 
was centrifuged to separate the FYCSMNP of the supernatant at the following selected 
times: 0.5, 1, 2, 4, 6, 24 and 48 h. After each centrifugation, the FYCSMNPs returned to 
the flask, where 10 mL of the same solution were added and the flasks returned to the 
orbital shaker and to the oven, to continue the release of the drug.  The supernatant 
separated in the centrifugation was measured by UV-Vis spectrophotometry at 480 nm 
to identify the concentration of drug that was released in each solution at each time, 
using the calibration curves shown in Figure 5. 
The whole process of analysis of the drug release tests was also repeated with 
the CCYSMNP loaded with OME. But the supernatant was measured by UV-Vis 
spectrophotometry at 300 nm to quantify the concentration of the OME that was 
released in each solution, using the calibration shown in the Figure 5. 
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4 Results and Discussion 
 
4.1 Synthesis of iron oxide nanoparticles 
The particles produced by SCS with citric acid and with the tangerine extract, by the 
procedure described in the previous chapter, are shown in Figure 6. It is noted that the 
particles produced with citric acid are magnetic, in opposition to the particles produced with 
the extract.  
 
 
Figure 6 – Nanoparticles produced with SCS. (A) Nanoparticles produced with citric acid without magnetic 
influence. (B) Nanoparticles produced with citric acid in the presence of a magnet. (C) Nanoparticles produced 
with tangerine extract without magnetic influence. (D) Nanoparticles produced with tangerine extract in the 
presence of a magnet. 
 
X-ray diffraction (XRD) was used to characterize the crystallography of the obtained 
MNPs. The XRD spectrum is presented in Figure 7 and shows characteristic peaks at 30.32º 
(220), 35.70º (311), 43.35º (400), 53.69º (422), 57.18º (511) and 62.82º (440), corresponding 
to magnetite nanoparticles. Peaks were referenced with standard peaks in the Joint Committee 
on Powder diffraction standard (JCPDS) file (PDF  N° 65– 3107) 83,84. Therefore, the 
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investigation of phase by XRD confirms that the crystal structure of the core synthesized with 
the citric acid corresponds to that of magnetite. The average particle size calculated by the 
Halder–Wagner method is around 19.3 nm. 
 
 
Figure 7- XRD patterns of the magnetic cores synthesized with citric acid. 
 
The XRD spectra of the nanoparticles produced with the tangerine extract, in Figure 8, 
shows characteristic peaks at 18.47°, 23.20°,  29.01º, 34.50º, 42.86º, 45.38°, 48.29º and 
57.39º,which does not correspond to magnetite nanoparticles, as referenced with standard 
peaks in the Joint Committee on Powder diffraction standard (JCPDS) file 
(PDF N° 65-3107) 83,84. 
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Figure 8 - XRD patterns of the magnetic cores synthesized with the tangerine extract. 
 
Taking into consideration the non-magnetic behavior of the nanoparticles synthesized 
with the tangerine extracts (as shown in Figure 6), not corresponding to the crystal structure 
of magnetite nanoparticles, it was decided to not continue the rest of the methodology with 
the particles produced with the tangerine extracts. 
 
4.2 The effects of the functionalization 
 
The spectral analysis done by Fourier transform infrared spectrometry (FT-IR) was 
performed to study the effects of the functionalization. The comparison of the spectra of the 
nanocomposites before and after functionalization is shown in Figure 9. The presence of 
magnetite is noticed in the absorption bands of 564 cm-1, 1635 cm-1 and 3436 cm-1. The first 
band corresponds to the vibration of the Fe–O bond and the latter two can be attributed to the 
bending and stretching vibrations of the surface –OH groups present in Fe3O4 85,86. The 
absorption bands at 1384 cm-1 , 1458 cm-1, 1632 cm-1, 2917 cm-1 and 3436 cm-1 represent the 
C-O, O-H, C=O, C-H and O-H bonds respectively, which indicate that there are carboxylic 
acid groups in the samples 7. 
In the functionalized sample, the increase in the intensity of the absorption bands at 
1384 cm-1 and 1632 cm-1 represents the increase in the C-O and C=O bonds of the carboxylic 
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acid groups 87. This indicates the increase of the carboxyl, which are responsible for making 
the nanocomposites more acidic. The presence of these groups in nanocomposites can 
improve the colloidal stability and monodispersibility in aqueous solutions 7. 
 
 
Figure 9 - FT-IR spectra of the functionalized and non-functionalized YCSMNP.  
 
4.3 Yield of the nanomaterials obtained 
The yield of the production of the nanomaterials is shown in Table 1. For the 
synthesis, according to the stoichiometry shown in equation 1, for each mol of Fe(NO3)3 
considered, 0.85 mol of citric acid is needed and 0.33 mol of Fe3O4 is produced. In this work, 
using 0.01296 mol of Fe(NO3)3 and 0.01103 mol of citric acid, 0.00384 mol of Fe3O4 was 
obtained, corresponding to an yield of reaction of 89.79%,.  
The yield in the first step of the coating process is 24.77%, producing an average of 
0.1757 g of material in each process. In the second step of the coating, a loss of 35% of the 
mass in the carbonization was observed. In the following steps of the process, an additional 
loss of mass of 5.60% was observed in the etching process and 45% in the acid treatment. In 
the functionalization with Pluronic, an increase of 6% was observed in the mass of the 
nanostructures. 
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Table 1- Yield of the nanomaterials obtained. 
  
Mass 
(g) 
Total  
mass(g) 
Final 
mass (g) 
Yield 
(%) 
Synthesis 
Fe(NO3)3 5.234 7.5538 0.8889 89.79 
Citric Acid 2.3198 
Coating 
MNPs 0.25 0.7094 0.1757 24.77 
Formaldehyde 0.1635 
TEOS 0.1959 
Resorcinol 0.1 
Carbonization MNPs 3.33 3.33 2.2176 65.00 
Etching MNPs 0.1 
 
0.094 94.40 
HNO3 MNPs 0.9053 
 
0.4921 54.36 
Funcionalization MNPs 0.04 
 
0.0426 106 
 
4.4 Capacity and efficiency of drug loading 
The DLC (μg.μg-1) and DLE (%) were studied for solutions of two drugs, DOX and 
OME, with the functionalized CCYSMNPs. For the studies with DOX a solution media of 
PBS pH 7.4 was used and for the studies with OME, distilled water was used. The results are 
shown in Table 2.  
 
Table 2 - Results of drug loading for DOX and OME. 
Drug DLC (μg.μg-1) DLE (%) 
Doxorubicine 0.936 93.6 
Omeprazole 0.335 33.5 
 
As observed, both DLC and DLE was higher when DOX was considered 
(0.936 μg.μg-1 and 93.6% respectively), than those values obtained when OME was loaded 
(0.335 μg.μg-1 and 33.5%). Comparing the results obtained with DOX with previous works, it 
can be noticed that the obtained values are very similar, 0.914 μg·μg-1 and 91.4% 7 for DLC 
and DLE, respectively for the nanomaterial with magnetic core (magnetite) synthetized by co-
precipitation and with  loading process of 24 h. 
The loading results of DOX can be compared with an others drug delivery system. A 
polypeptide-based nanoparticles system have a DLE of around 97% 88. In other study, 
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magnetic NCs consist on hybrid nanostructure, which were obtained by an oil-in-water 
microemulsion, shows a DLE up to 24.39% 89. 
 
4.5 The effect of pH on drug release 
 
The analysis of the pH effect on the drug release is very important due to the 
difference between the pH of the normal tissues (pH 7.4) and the extracellular environment of 
the tumor (pH < 6.5). A pH-sensitive drug delivery system is usually used to improve the drug 
release in tumor tissues due to the low pH value of tumor tissues 90. If more drug is released in 
the more acidic environment, the lower will be the side effects and damage to the healthy 
cells. In these release tests higher drug release values in acidic medium were expected for 
both of the drugs studied.  
The cumulative drug release (%) of the amount of DOX retained in the 
nanocomposites are 39.33%, 29.05% and 7.10% in PBS solutions with pH 4.5, pH 6.0 and 
pH 7.4, respectively, Figure 10a. These results can be expressed in cumulative concentrations 
of 51.70 μg.mL-1, 38.64 μg.mL-1 and 7.94 μg.mL-1, represent in weight DOX quantities of 
516.97 μg, 386.42 μg and 79.37 μg in PBS solutions with pH 4.5, pH 6.0 and pH 7.4, 
respectively. The drug release over time is represented in Figure 10b. As expected, for DOX, 
the largest amount of drug released was obtained in the acid medium, which indicates that the 
FYCSMNPs works as a DOX drug delivery system. 
 
 
Figure 10 - (a) Cumulative DOX release (%). (b) Cumulative DOX release (μg). 
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Analyzing the results obtained for DOX release, it can be concluded that they are 
slightly higher than those obtained in previous works (21%) which the magnetic core 
(magnetite) of the nanomaterial synthetized by co - precipitation 7, having a better delivery in 
the more acid medium (pH < 6.5). 
A polypeptide-based nanoparticles system also have a better drug release (60%) at the 
most acid medium (pH 5.5) tested when compared to the drug release (22%) at pH 7.4, so the 
health tissue medium, 88. Drug release of 20% and 80% at pH 7.4 and pH 5.5 have been 
obtained with magnetic NCs is a hybrid nanostructure were obtained by an oil-in-water 
microemulsion, respectively 89 . 
The cumulative drug release (%) of the amount of OME retained in the 
nanocomposites are 35.01%, 49.53% and 49.21% in PBS solutions with pH 4.5, pH 6.0 and 
pH 7.4, respectively, Figure 11a. These results can be expressed in cumulative concentrations 
of 12.50 μg.L1, 19.21 μg.mL-1 and 19.44 μg.mL-1, which represent in weight of OME the 
quantities of 125.01 μg, 192.08 μg and 194.37 μg in PBS solutions with pH 4.5, pH 6.0 and 
pH 7.4, respectively. The drug release over time is represented in Figure 11b.  
In the studies carried out with OME, the results were not as expected, since as OME is 
a drug used in the treatment of active duodenal ulcers, active benign gastric ulcers, gastro-
esophageal reflux disease, a much greater drug release in the acidic pH was desired.  
 
 
Figure 11- (a) Cumulative OME release (%). (b) Cumulative OME release (μg). 
 
The drug release has shown to have a dependence with the pH of the targeting cells, 
for the DOX, the medium with pH 4.5 and for the OME, pH 6.0. Therefore, pH controlled 
drug release would be a viable application to the synthesized material. For this application, 
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the FYCSMNPs would be conducted to the target with a magnetic field and the pH of the 
environment would act on the release of the drug. The disadvantage is that a large part of the 
drug loaded in the particles was not released.  
In conclusion, this research demonstrates that the FYCSMNPs developed have an 
outstanding ability as drug nanocarriers, in the case of the Doxorubicine with great ability to 
load high content of the drug. 
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5. Conclusions and Future Research 
 
5.1 Conclusions 
 
Based on the premise of optimizing yolk-shell magnetic nanocomposites for 
applications in biomedicine, this thesis was conducted aiming to obtain higher amount of drug 
release in a more acidic medium, mimicking the medium of tumor tissues. Thus, considering 
all the adjustments made during the synthesis, coating, functionalization and loading and 
release of the drug, the final result obtained shows a quantity of released DOX much higher in 
the acid medium when compared to the equivalent pH in normal cells. But, in the case of 
OME the higher amount of drug was releases at pH 6.0.  
A disadvantage of the developed system was the high amount of both drugs retained in 
the material, still requiring furher optimization to improve the drug exploitation and to obtain 
better yield of release. Another parameter that needs optimization is the first step of the 
coating process, to try to reduce the amount of mass loss in this step of the methodology. 
 
5.2 Future Research 
 
Looking forward to develop a better drug delivery system, some details of the process 
need to be polished. The coating process needs to be study, to achieve a lower value of mass 
loss. Relating to loading of the drugs, the loading of OME needs to be improved, so that a 
higher quantity of the drug can be loaded into the FYCSMNP. To try to solve this problem, 
maybe instead of 48 h, the loading process could be longer. Also, the drug release needs to be 
improved for both drug, so that fewer amount of them are maintained in the nanocomposites. 
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Figures I to IX shows the equipments used during the experiments performed in this work. 
 
Figure I – Peristaltic pump ISM 845, ISMATEC. 
 
Figure II - Drying oven FD 115, Binder. 
 
Figure III - Magnetic stirring plate IKA® C-MAG HS 7 with temperature control IKA® ETS-D5. 
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Figure IV - Centrifugal MPW-260R, MPW Med. Instruments. 
 
Figure V – Analytical mill, IKA A11 basic. 
 
Figure VI – Ultrasons-H, P-Selecta. 
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Figure VII - Vertical tubular furnace ROS 50/250/12, Thermoconcept. 
 
 
Figure VIII - Orbital shaker IKA® KS 130 basic. 
 
 
Figure IX - T70 UV-VIS spectrophotometer, PG Instruments Ltd. 
 
